Fineline Cube

Follow:
14435 Articles
GSK's Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma
Others

GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma

Sanofi's Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
CompanyDrug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials
CompanyDeals

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases
CompanyDeals

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases

SinoCellTech's SCT640C Injection Receives NMPA Approval for RA Clinical Trials
CompanyDrug

SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials

Hengrui Pharmaceuticals' HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval
CompanyDrug

Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval

Cryofocus Medtech's Asthma Cryoablation System Granted FDA Breakthrough Device Designation
CompanyMedical Device

Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation

3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707
CompanyDeals

3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707

Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion
Company

Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer
CompanyDrug

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer

Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO
CompanyDeals

Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO

Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization
CompanyDeals

Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization